Dana-Farber Cancer Institute: Smoldering Multiple Myeloma trials

The registry lists 10 Smoldering Multiple Myeloma studies with Dana-Farber Cancer Institute as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 2 6No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• PROFAST Intervention in Precursor Multiple MyelomaCompletedNCT05565638Not applicableResults posted
• Investigation of Metformin for the Prevention of Progression of Precursor Multiple MyelomaActive, not recruitingNCT04850846Phase 2Results posted
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaActive, not recruitingNCT03236428Phase 2Results posted
• Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple MyelomaCompletedNCT02916771Phase 2Results posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaCompletedNCT02279394Phase 2Results posted
• CAR- PRISM (PRecision Intervention Smoldering Myeloma)Active, not recruitingNCT05767359Phase 2
• Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple MyelomaCompletedNCT01955395Not applicable
• Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527